Sunday, January 10, 2016

The Commercial Ecosystem of Biotechnology in China

Since China’s first commercial cloning company was established in September 2014 in the eastern Shandong Province with the birth of three pure-blooded Tibetan mastiff puppies (prior to this, cloning in China had been limited to scientific research), more and more companies have shown interest in investing in the technology for commercial use, especially animal husbandry. China has made rapid and tremendous progress in fields like genome sequencing and cloning field.
At the end of 2015, Chinese scientists signed a deal to establish a commercial animal cloning center in the Tianjin Economic and Technological Development Area (TEDA), edging the controversial science closer to mainstream acceptance.


China has great hopes in biotechnology industry, but also doubts to the same degree. Some participants are worried that biotechnology will become the next one after the Internet bubble since it probably will be another popular investment spot right after the Internet. However, biotechnology industry was born with doubts and cautions which is different from the advent of the Internet. Hence, it leads us to believe that the focus on biotechnology is unlikely to result in “irrational prosperity”. Meanwhile, the emerging biotechnology is demonstrating a diverse commercial ecosystem from the Internet industry.


In my opinion, biotechnology is of great importance for developing countries to solve many urgent problems such as human healthcare, food supply, agriculture and environmental protection. China, as an emerging market, lacks of commercial experience as well as original innovations, and the suitable and effective ways to transform the science and technology achievements into products. However, given the momentum underway, the sheer scale of the effort expended and its immense market size, China will ultimately create a healthy and prosperous commercial ecosystem for the development of biotechnology industry.

Wednesday, January 6, 2016

Rani Jarkas Investments Advice: Invest in Indonesia: Reforming Amid Development By...

Rani Jarkas Investments Advice: Invest in Indonesia: Reforming Amid Development By...: According to the UNCTAD 2014 World Investment Report , Indonesia is one of the three most attractive destination for multinational compa...

Rani Jarkas Investments Advice: 投资在印尼:改革与发展并存 王雷(Rani Jarkas)

Rani Jarkas Investments Advice: 投资在印尼:改革与发展并存 王雷(Rani Jarkas): 根据 联合国贸易和发展会议 发布的 2014 年《世界投资报告》 , 印尼是 2014-2016 年度最受跨国公司欢迎的三大投资地之一, 排在 印度 和 巴西 之前。印尼政府一贯鼓励 外国直接投资 在印尼绝大多数产业。许多全球大型公司,如 苹果 、 米其林 、 百度 和 富...

投资在印尼:改革与发展并存 王雷(Rani Jarkas)


根据联合国贸易和发展会议发布的2014年《世界投资报告》,印尼是2014-2016年度最受跨国公司欢迎的三大投资地之一,排在印度和巴西之前。印尼政府一贯鼓励外国直接投资在印尼绝大多数产业。许多全球大型公司,如苹果、米其林、百度和富士康,都计划增加在印尼的投资。


2015年11月,全球信用评级机构惠誉国际信用评级确认印尼国家主权信用评级为“BBB-”,展望为稳定,承认印尼在当今经济困境下坚持不懈的结构性改革成效。

然而,印尼目前确实处在5年来经济增长最为缓慢的阶段,亚洲基础设施投资银行(简称“亚投行”)雅加达主任史蒂文·泰伯评论道“变化正在发生,但投资者仍需耐心。”

赛德思投资董事长王雷(Rani Jarkas)在印尼有多年的投资经验。他表示:“印尼拥有广阔的市场、丰富的自然资源和不断增长的内需,我相信印尼在未来仍将是最受国际投资者青睐的东南亚国家。”


Invest in Indonesia: Reforming Amid Development By Rani Jarkas


According to the UNCTAD 2014 World Investment Report, Indonesia is one of the three most attractive destination for multinational companies for 2014-2016, ahead of India and Brazil. The Indonesian government encourages foreign direct investment in most sectors of the Indonesian economy. Many international giants, such as Apple Inc., Michelin, Baidu, and Foxconn, are planning to increase direct investment in Indonesia.

In 2015, the government of Indonesia unveiled its eight economic stimulus package to boost economic growth, investment and trade. The latest edition of the series of packages, announced by Economic Chief Minister Darmin Nasution at the end of 2015, involves fiscal and non-fiscal incentives to open up its oil refinery development across Indonesia to private investors’ participation.



Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of experience in Indonesia, said, “I believe that Indonesia will remain the most attractive country in Southeast Asia for international investors, given its enormous market capacity, abundant natural resources and growing internal demand.”


中国生物科技产业持续发展潜力巨大 - 王雷(Rani Jarkas)


生物科技产业是当今全球发展最快的领域之一。特别是中国,生物科技产业都保持着两位数的增长。中国的总体医疗支出在过去五年内翻了三番,从2010年的2,817亿美元攀升至2015年的8,536亿美元。

中国把发展生物科技作为国家的首要目标之一。由于人口众多、经济发展迅速、人民收入不断增加,中国已成为了生物产品的一大重要市场,并在生物技术产品的研发和生产上扮演着关键的角色,吸引了来自私人和公众投资者的关注。

2015年5月,中国国务院公布了一项为期十年的国家规划——《中国制造2025》,生物科技就是其中十大重点领域之一。该规划经李克强总理签批 ,预测中国广义生物产业市场规模到2020年约为6万亿元。

最近,中国卫生部部长陈竺承诺中国2016年至2020年的“十三五”规划中计划投入118亿美元推动生物医药创新。

赛德思投资董事长王雷(Rani Jarkas)在生物科技领域有多年的投资经验。他表示:“中国政府在生物产业创新上的雄心和投入,使得中国在这一领域拥有保持高速发展的巨大潜力,将为全社会带来深远影响。”


China Shows Great Potential for Sustained Growth in Biotechnology Industry By Rani Jarkas

Biotechnology is one of the most fast-growing industries nowadays in the world. China, in particular, has seen double-digit growth in its biotechnology industry. Its total medical expenditure tripled over the past five years from $281.7 billion in 2010 to $853.6 billion in 2015.

China has made growing the biotechnology industry one of its top national priorities. With its large population, rapid economic growth and people’s higher income, China becomes an important market for biotech products and plays a key role in biotech product development and manufacturing, drawing more attention from investors – both private and public.

In May 2015, China’s State Council has unveiled a ten-year national plan, “Made in China 2025”, with biotechnology as one of the 10 key sectors. The plan, endorsed by Premier Li Keqiang, forecasts the market of China’s general biotechnology industry will reach 6 trillion yuan by 2020.

Most recently, Zhu Chen, China’s Minister of Health, has pledged that the country plans to spend $11.8 billion to increase biopharma innovation in its 13th Five-Year Plan, which covers the period 2016-2020.

Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of experience in biotech and life science sector, said, “With the Chinese government’s high ambitions and commitment to become a driver of innovation in biotechnology industry, China has great potential to maintain its rapid growth in this field and provide tremendous benefits to society.”